{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:40:57Z","timestamp":1789504857805,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022NSFSC1554"],"award-info":[{"award-number":["2022NSFSC1554"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903099"],"award-info":[{"award-number":["81903099"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.bioorg.2025.108555","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T19:27:54Z","timestamp":1746473274000},"page":"108555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of (E)-2-cyano-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)-3-(1H-indol-3-yl)acrylamide as a novel TDO inhibitor for cancer treatment"],"prefix":"10.1016","volume":"161","author":[{"given":"Xiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108555_bb0005","doi-asserted-by":"crossref","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108555_bb0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108555_bb0015","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1186\/s12885-021-08855-9","article-title":"Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR\/c-Myc dependent manner","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108555_bb0020","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00726-010-0787-9","article-title":"Kynurenine metabolism in health and disease","volume":"41","author":"Kolodziej","year":"2011","journal-title":"Amino Acids"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108555_bb0025","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/2326-6066.CIR-15-0095","article-title":"Tumoral immune resistance mediated by enzymes that degrade tryptophan","volume":"3","author":"van Baren","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"Pt 2","key":"10.1016\/j.bioorg.2025.108555_bb0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1042\/BST0370408","article-title":"Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase","volume":"37","author":"Rafice","year":"2009","journal-title":"Biochem. Soc. Trans."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108555_bb0035","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1158\/0008-5472.CAN-12-0549","article-title":"The kynurenine pathway in brain tumor pathogenesis","volume":"72","author":"Adams","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108555_bb0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fimmu.2015.00034","article-title":"Tryptophan-degrading enzymes in tumoral immune resistance","volume":"6","author":"van Baren","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.108555_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104348","article-title":"Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO)","volume":"104","author":"Zhang","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108555_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2024.2332509","article-title":"Identification of putative Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) dual inhibitors for triple-negative breast cancer therapy","author":"Paranthaman","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2025.108555_bb0055","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.2147\/OTT.S252929","article-title":"TDO promotes hepatocellular carcinoma progression","volume":"13","author":"Li","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108555_bb0060","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1073\/pnas.1113873109","article-title":"Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase","volume":"109","author":"Pilotte","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108555_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/2326-6066.CIR-19-0040","article-title":"Tryptophan 2,3-dioxygenase expression identified in human hepatocellular carcinoma cells and in Intratumoral Pericytes of Most cancers","volume":"8","author":"Hoffmann","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bioorg.2025.108555_bb0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinorgbio.2019.02.004","article-title":"Pt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immunomodulators","volume":"195","author":"Hua","year":"2019","journal-title":"J. Inorg. Biochem."},{"issue":"sup1","key":"10.1016\/j.bioorg.2025.108555_bb0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/14756366.2016.1170013","article-title":"Insights into the mechanism of inhibition of tryptophan 2,3-dioxygenase by isatin derivatives","volume":"31","author":"Pantouris","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108555_bb0080","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-014-1549-4","article-title":"Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer","volume":"63","author":"Prendergast","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bioorg.2025.108555_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116852","article-title":"Discovery, synthesis and biological evaluation of novel isoquinoline derivatives as potent indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase dual inhibitors","volume":"279","author":"Lin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108555_bb0090","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.1021\/acs.jmedchem.5b00921","article-title":"Identification of substituted Naphthotriazolediones as novel tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening","volume":"58","author":"Wu","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108555_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112703","article-title":"Discovery and structure-activity relationship studies of 1-aryl-1-naphtho[2,3-][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO)","volume":"207","author":"Pan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108555_bb0100","doi-asserted-by":"crossref","first-page":"8303","DOI":"10.1021\/acs.jmedchem.1c00303","article-title":"X-ray structure-guided discovery of a potent, orally bioavailable, dual human Indoleamine\/tryptophan 2,3-dioxygenase (hIDO\/hTDO) inhibitor that shows activity in a mouse model of Parkinson's disease","volume":"64","author":"Ning","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108555_bb0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.imlet.2019.11.004","article-title":"The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO)","volume":"217","author":"Vega","year":"2020","journal-title":"Immunol. Lett."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108555_bb0110","doi-asserted-by":"crossref","first-page":"14543","DOI":"10.1021\/acs.jmedchem.4c01360","article-title":"Structural insights into protein-inhibitor interactions in human tryptophan dioxygenase","volume":"67","author":"Geeraerts","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108555_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112703","article-title":"Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO)","volume":"207","author":"Pan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108555_bb0120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinorgbio.2019.02.004","article-title":"Pt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immunomodulators","volume":"195","author":"Hua","year":"2019","journal-title":"J. Inorg. Biochem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108555_bb0125","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108555_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116852","article-title":"Discovery, synthesis and biological evaluation of novel isoquinoline derivatives as potent indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase dual inhibitors","volume":"279","author":"Lin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108555_bb0135","first-page":"4800","article-title":"Synthesis and pharmacology of benzoxazines as highly selective antagonists M-4 muscarinic receptors. (vol 45, pg 3096, 2002)","volume":"45","author":"Bohme","year":"2002","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2025.108555_bb0140","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.1021\/jm3002845","article-title":"Low molecular weight Amidoximes that act as potent inhibitors of lysine-specific demethylase 1","volume":"55","author":"Hazeldine","year":"2012","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2025.108555_bb0145","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bmcl.2012.12.050","article-title":"Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold","volume":"23","author":"Valdenaire","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"20","key":"10.1016\/j.bioorg.2025.108555_bb0150","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1021\/jm0209026","article-title":"Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B","volume":"45","author":"Andersen","year":"2002","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108555_bb0155","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1021\/acs.jmedchem.5b00270","article-title":"Design, synthesis, and structure-activity relationship studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives as a new class of Src inhibitors with potent activities in models of triple negative breast Cancer","volume":"58","author":"Zhang","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108555_bb0160","first-page":"504","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model, Comput Struct","volume":"13","author":"Yadav","year":"2015","journal-title":"Biotechnol. J."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825004353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825004353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:24:22Z","timestamp":1762223062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825004353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"alternative-id":["S0045206825004353"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108555","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of (E)-2-cyano-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)-3-(1H-indol-3-yl)acrylamide as a novel TDO inhibitor for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108555"}}